Literature DB >> 18606657

IFN-alpha induces transcription of hypoxia-inducible factor-1alpha to inhibit proliferation of human endothelial cells.

Scott A Gerber1, Jordan S Pober.   

Abstract

Expression of hypoxia-inducible factor (HIF)-1alpha, a transcription factor subunit increased by protein stabilization in response to hypoxia, is increased in human endothelial cells (ECs) by IFN-alpha under normoxic conditions. IFN-alpha increases HIF-1alpha transcript levels within 2 h by up to 50% and doubles HIF-1alpha protein expression. Based on pharmacological inhibition studies, the increase in HIF-1alpha mRNA involves new transcription, is independent of new protein synthesis, and requires JAK signaling. Protein knockdown by small interfering RNA confirms the involvement of JAK1 and TYK2, as well of IFN-stimulated gene factor 3 (ISGF3). IFN-gamma does not significantly induce HIF-1alpha mRNA, but increases the magnitude and duration of the IFN-alpha effect. IFN-alpha-induced HIF-1alpha protein translocates to the nucleus and can bind to hypoxia response elements in DNA. However, IFN-alpha treatment fails to induce transcription of several prototypic HIF-responsive genes (VEGF-A, PPARgamma, and prostacyclin synthase) due to an insufficient increase in HIF-1alpha protein levels. Although certain other HIF-responsive genes (PHD3 and VEGF-C) are induced following IFN-alpha and/or IFN-gamma treatment, these responses are not inhibited by siRNA knockdown of HIF-1alpha. Additionally, IFN-alpha induction of ISGF3-dependent genes involved in innate immunity (viperin, OAS2, and CXCL10) are also unaffected by knockdown of HIF-1alpha. Interestingly, knockdown of HIF-1alpha significantly reduces the capacity of IFN-alpha to inhibit endothelial cell proliferation. We conclude that IFN-alpha induces the transcription of HIF-1alpha in human endothelial cells though a JAK-ISGF3 pathway under normoxic conditions, and that this response contributes to the antiproliferative activity of this cytokine.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18606657      PMCID: PMC2737178          DOI: 10.4049/jimmunol.181.2.1052

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  69 in total

1.  HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing.

Authors:  M Ivan; K Kondo; H Yang; W Kim; J Valiando; M Ohh; A Salic; J M Asara; W S Lane; W G Kaelin
Journal:  Science       Date:  2001-04-05       Impact factor: 47.728

2.  A non-hypoxic, ROS-sensitive pathway mediates TNF-alpha-dependent regulation of HIF-1alpha.

Authors:  J J Haddad; S C Land
Journal:  FEBS Lett       Date:  2001-09-14       Impact factor: 4.124

3.  Regulation of the promoter activity of interferon regulatory factor-7 gene. Activation by interferon snd silencing by hypermethylation.

Authors:  R Lu; W C Au; W S Yeow; N Hageman; P M Pitha
Journal:  J Biol Chem       Date:  2000-10-13       Impact factor: 5.157

Review 4.  Hypoxia-inducible factor 1: oxygen homeostasis and disease pathophysiology.

Authors:  G L Semenza
Journal:  Trends Mol Med       Date:  2001-08       Impact factor: 11.951

Review 5.  Angiogenesis: regulators and clinical applications.

Authors:  S Liekens; E De Clercq; J Neyts
Journal:  Biochem Pharmacol       Date:  2001-02-01       Impact factor: 5.858

6.  HIF-1alpha controls keratinocyte proliferation by up-regulating p21(WAF1/Cip1).

Authors:  Young-Suk Cho; Jae-Moon Bae; Yang-Sook Chun; Jin-Ho Chung; Yoon-Kyung Jeon; In-San Kim; Myung-Suk Kim; Jong-Wan Park
Journal:  Biochim Biophys Acta       Date:  2007-12-08

7.  Alloimmunity to human endothelial cells derived from cord blood progenitors.

Authors:  Yajaira Suárez; Benjamin R Shepherd; Deepak A Rao; Jordan S Pober
Journal:  J Immunol       Date:  2007-12-01       Impact factor: 5.422

8.  Antiproliferative activity of the human IFN-alpha-inducible protein IFI44.

Authors:  L C Hallen; Y Burki; M Ebeling; C Broger; F Siegrist; K Oroszlan-Szovik; B Bohrmann; U Certa; S Foser
Journal:  J Interferon Cytokine Res       Date:  2007-08       Impact factor: 2.607

9.  Interferon-gamma induces human vascular smooth muscle cell proliferation and intimal expansion by phosphatidylinositol 3-kinase dependent mammalian target of rapamycin raptor complex 1 activation.

Authors:  Yinong Wang; Yalai Bai; Lingfeng Qin; Pei Zhang; Tai Yi; Stephanie A Teesdale; Liping Zhao; Jordan S Pober; George Tellides
Journal:  Circ Res       Date:  2007-07-26       Impact factor: 17.367

Review 10.  HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation.

Authors:  John D Gordan; Craig B Thompson; M Celeste Simon
Journal:  Cancer Cell       Date:  2007-08       Impact factor: 31.743

View more
  23 in total

1.  IFN-γ attenuates hypoxia-inducible factor (HIF) activity in intestinal epithelial cells through transcriptional repression of HIF-1β.

Authors:  Louise E Glover; Karina Irizarry; Melanie Scully; Eric L Campbell; Brittelle E Bowers; Carol M Aherne; Douglas J Kominsky; Christopher F MacManus; Sean P Colgan
Journal:  J Immunol       Date:  2011-01-03       Impact factor: 5.422

2.  AML1/ETO cooperates with HIF1α to promote leukemogenesis through DNMT3a transactivation.

Authors:  X N Gao; F Yan; J Lin; L Gao; X L Lu; S C Wei; N Shen; J X Pang; Q Y Ning; Y Komeno; A L Deng; Y H Xu; J L Shi; Y H Li; D E Zhang; C Nervi; S J Liu; L Yu
Journal:  Leukemia       Date:  2015-03-02       Impact factor: 11.528

3.  Chromatin dynamics of gene activation and repression in response to interferon alpha (IFN(alpha)) reveal new roles for phosphorylated and unphosphorylated forms of the transcription factor STAT2.

Authors:  Barbara Testoni; Christine Völlenkle; Francesca Guerrieri; Sabine Gerbal-Chaloin; Giovanni Blandino; Massimo Levrero
Journal:  J Biol Chem       Date:  2011-04-15       Impact factor: 5.157

4.  Activities of multiple cancer-related pathways are associated with BRAF mutation and predict the resistance to BRAF/MEK inhibitors in melanoma cells.

Authors:  Dingxie Liu; Xuan Liu; Mingzhao Xing
Journal:  Cell Cycle       Date:  2013-10-29       Impact factor: 4.534

Review 5.  JAK Inhibitors Suppress Innate Epigenetic Reprogramming: a Promise for Patients with Sjögren's Syndrome.

Authors:  Amandine Charras; Pinelopi Arvaniti; Christelle Le Dantec; Marina I Arleevskaya; Kaliopi Zachou; George N Dalekos; Anne Bordon; Yves Renaudineau
Journal:  Clin Rev Allergy Immunol       Date:  2020-04       Impact factor: 8.667

6.  Type I interferons induced by radiation therapy mediate recruitment and effector function of CD8(+) T cells.

Authors:  Joanne Y H Lim; Scott A Gerber; Shawn P Murphy; Edith M Lord
Journal:  Cancer Immunol Immunother       Date:  2013-12-20       Impact factor: 6.968

7.  Double knockdown of prolyl hydroxylase and factor-inhibiting hypoxia-inducible factor with nonviral minicircle gene therapy enhances stem cell mobilization and angiogenesis after myocardial infarction.

Authors:  Mei Huang; Patricia Nguyen; Fangjun Jia; Shijun Hu; Yongquan Gong; Patricia E de Almeida; Li Wang; Divya Nag; Mark A Kay; Amato J Giaccia; Robert C Robbins; Joseph C Wu
Journal:  Circulation       Date:  2011-09-13       Impact factor: 29.690

8.  Toll-like receptor 3 regulates angiogenesis and apoptosis in prostate cancer cell lines through hypoxia-inducible factor 1 alpha.

Authors:  Alessio Paone; Roberta Galli; Chiara Gabellini; Dmitriy Lukashev; Donatella Starace; Agnes Gorlach; Paola De Cesaris; Elio Ziparo; Donatella Del Bufalo; Michail V Sitkovsky; Antonio Filippini; Anna Riccioli
Journal:  Neoplasia       Date:  2010-07       Impact factor: 5.715

9.  IFN-γ mediates the antitumor effects of radiation therapy in a murine colon tumor.

Authors:  Scott A Gerber; Abigail L Sedlacek; Kyle R Cron; Shawn P Murphy; John G Frelinger; Edith M Lord
Journal:  Am J Pathol       Date:  2013-04-12       Impact factor: 4.307

10.  Interferon-gamma induces prolyl hydroxylase (PHD)3 through a STAT1-dependent mechanism in human endothelial cells.

Authors:  Scott A Gerber; Bogdan Yatsula; Cheryl L Maier; Timothy J Sadler; Laurence W Whittaker; Jordan S Pober
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-07-02       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.